Recombinant platelet factor-4 (rPF4): Started a 40-patient Phase II comparison study

Repligen Corp. (RGEN) Product: Recombinant platelet factor-4 (rPF4) Indication: Reverse the anticoagulant effects of heparin in cardiac catheterization patients Status: Started a 40-patient Phase II ...